Acromegaly

More than half of adults with acromegaly receiving the somatostatin receptor ligand pasireotide achieved normal insulin-like growth factor I levels, according to data from a long-term real-world study.

CHICAGO —In this video exclusive, John Carmichael, MD, discusses some of the pituitary research presented at ENDO 2023, including treatments for Cushing’s syndrome and adipose effects following acromegaly cure.

R. Scott Struthers, PhD, had a lab job synthesizing peptide hormones as a college freshman. That experience launched a career featuring discovery of novel agents for endocrine diseases, women’s health conditions and cancers.

Among adults with acromegaly, concomitant type 2 diabetes was associated with increased risks for overall mortality and for cardiovascular mortality and morbidity, researchers reported in The Journal of Clinical Endocrinology & Metabolism.

Endoscopic transsphenoidal surgery has the best remission rates and fewest postoperative complications for adults with acromegaly, according to findings from a systematic review.

ATLANTA — More than 90% of adults with acromegaly remained responders to oral octreotide 3 years after initiating treatment, according to findings from the MPOWERED open-label extension study presented at ENDO 2022.

ATLANTA — In this video exclusive, Maria Fleseriu, MD, FACE, reviews the pituitary research presented at the annual meeting of the Endocrine Society in Atlanta.

Among adults with controlled acromegaly, postmenopausal women had higher growth hormone levels than men despite similar insulin-like growth factor I levels, according to study data.

Adults with acromegaly are more likely to experience a vertebral fracture than those without the disease, and high growth hormone levels increase fracture risk, according to study data from Italy.

Adults with acromegaly have more comorbidities and are prescribed more concomitant medications than those without acromegaly, according to study findings published in Pituitary.